US EditionPublished • loading... • Updated
Argenx Highlights 2026 Strategic Priorities
Summary by Hastings Tribune
3 Articles
3 Articles
argenx Highlights 2026 Strategic Priorities - argenx (NASDAQ:ARGX)
Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19,000 patients on treatment; and if approved, AChR-Ab seronegative gMG launch expected by end of 2026 Four registrational readouts expected in 2026, including first for empasiprubart, to advance toward next wave of 2027 commercial launches Successfully…
·New York, United States
Read Full Article
09:14 The publicly traded Ghent-based biotech company posted fourth-quarter revenue of $1.29 billion, thanks to its multi-purpose drug Vyvgart. This year, it also expects significant res...
·Belgium
Read Full ArticleCoverage Details
Total News Sources3
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
